Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: Implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides

Mucosal Immunology

Volumn 7, Issue 5, 2014, Pages 1165-1174

  Rollenhagen, C ^a,b   Lathrop, M J ^b   Macura, S L ^a   Doncel, G F ^c   Asin, S N ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; TENOFOVIR; RNA; ANTIVIRUS AGENT;

ARTICLE; CCR5+ T LYMPHOCYTE; CD38+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA INTEGRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HERPES SIMPLEX VIRUS 2; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MIXED INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; T LYMPHOCYTE; TREATMENT RESPONSE; UTERINE CERVIX MUCOSA; VIRION; VIRUS ACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; ANTIVIRAL ACTIVITY; EX VIVO STUDY; GEL; GENETIC TRANSCRIPTION; HUMAN CELL; MUCOSA INFLAMMATION; MUCOSAL IMMUNITY; ORGANISMAL INTERACTION; PROTECTION; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; UPREGULATION; UTERINE CERVIX; VIRUS CELL INTERACTION; VIRUS RELEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TRANSMISSION; VIROLOGY;

ANTIGENS, CD38; ANTIVIRAL AGENTS; CERVIX UTERI; FEMALE; GENE EXPRESSION REGULATION; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; TENOFOVIR; VIRUS REPLICATION;

EID: 84900532147     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.3     Document Type: Article

References (50)

1. Ghebremichael, M., Habtzgi, D. & Paintsil, E. Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub-Saharan Africa. BMC Res. Notes 5, 451 (2012).
2. Mmbaga, E.J., Leyna, G.H., Stray-Pedersen, B. & Klepp, K.I. Herpes simplex virus type-2 and human immunodeficiency virus infections in a rural population in Kilimanjaro Tanzania. East Afr. J. Public Health 8, 28-32 (2011).
3. Venkatesh, K.K. et al. The relative contribution of viral and bacterial sexually transmitted infections on HIV acquisition in southern African women in the Methods for Improving Reproductive Health in Africa study. Int. J.STDAIDS 22, 218-224 (2011).
4. Wald, A. & Link, K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185, 45-52 (2002).
5. Horbul, J.E., Schmechel, S.C., Miller, B.R., Rice, S.A. & Southern, P.J. Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture. PLoS ONE 6, e22638 (2011).
6. Zhu, J. et al. Persistence of HIV receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV acquisition. Nat. Med. 15, 886-892 (2009).
7. Drannik, A.G.,Nag,K., Sallenave, J.M. & Rosenthal,K.L. Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. J. Virol. 87, 7526-7538 (2013).
8. Fakioglu, E. et al. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion. J. Virol. 82, 9337-9344 (2008).
9. Sheth, P.M. et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J. Infect. Dis. 197, 1394-1401 (2008).
10. Li, H. et al. HSV-2 induces TLRs and NF-kappaB-dependent cytokines in cervical epithelial cells. Biochem. Biophys. Res. Commun. 379, 686-690 (2009).
11. Goodkin, M.L., Ting, A.T. & Blaho, J.A. NF-kappa B is required for apoptosis prevention during herpes simplex virus type 1 infection. J. Virol. 77, 7261-7280 (2003).
12. Asin, S.N., Eszterhas, S.K., Rollenhagen, C., Heimberg, A.M. & Howell, A. HIV type 1 infection in women: increased transcription of HIV type 1 in ectocervical tissue explants. J. Infect. Dis. 200, 965-972 (2009).
13. Rollenhagen, C. & Asin, S.N. IL-8 decreases HIV-1 transmission in peripheral blood lymphocytes and ectocervical tissue explants. J. Acquir. Immune Defic. Syndr. 54, 463-469 (2010).
14. Rollenhagen, C. & Asin, S.N. Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol. 4, 671-681 (2011).
15. Krzyzowska, M. et al. HSV-2 regulates monocyte inflammatory response via the Fas/FasL pathway. PLoS One 8, e70308 (2013).
16. Iijima, N., Mattei, L.M. & Iwasaki, A. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc. Natl. Acad. Sci. USA 108, 284-289 (2011).
17. Nakanishi, Y., Lu, B., Gerard, C. & Iwasaki, A. CD8 (+) T lymphocyte mobilization to virus-infected tissue requires CD4 (+) T-cell help. Nature 462, 510-513 (2009).
18. Lund, J.M., Linehan, M.M., Iijima, N. & Iwasaki, A. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol. 177, 7510-7514 (2006).
19. Koelle, D.M., Schomogyi, M. & Corey, L. Antigen-specific Tcells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J. Infect. Dis. 182, 662-670 (2000).
20. Biancotto, A. et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 111, 699-704 (2008).
21. McKinnon, L.R. & Kaul, R. Quality and quantity: mucosal CD4+ Tcells and HIV susceptibility. Curr. Opin. HIV AIDS 7, 195-202 (2012).
22. Jaspan, H.B. et al. Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J. Infect. Dis. 204, 1550-1556 (2011).
23. Shao, Y. et al. Keratinocytes play a role in the immunity to Herpes simplex virus type 2 infection. Acta Virol. 54, 261-267 (2010).
24. Carr, D.J. & Tomanek, L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr. Top.Microbiol. Immunol. 30, 47-65 (2006).
25. Thurman, A.R. & Doncel, G.F. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int. J. STD AIDS 23, 613-619 (2012).
26. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 333, 1168-1174 (2010).
27. Josefsson, L. et al. Single cell analysis of lymph node tissues from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS Pathog. 9, e1003432 (2013).
28. Saba, E. et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 3, 280-290 (2010).
29. Gorry, P.R. & Ancuta, P. Coreceptors and HIV pathogenesis. Curr. HIV/AIDS Rep. 8, 45-53 (2011).
30. Grivel, J.C., Shattock, R.J. & Margolis, L.B. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J. Transl. Med. 9 (Suppl 1), S6 (2011).
31. Grivel, J.C. et al. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS 21, 1263-1272 (2007).
32. Margolis, L. & Shattock, R. Selective transmission of CCR5-utilizing HIV-1: the & quot;gatekeeper" problem resolved?. Nat. Rev. Microbiol. 4, 312-317 (2006).
33. Andrei, G. et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 10, 379-389 (2011).
34. Vibholm, L. et al. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection. AIDS Res. Hum. Retroviruses 28, 1404-1411 (2012).
35. Grivel, J.C. & Margolis, L. Use of human tissue explants to study human infectious agents. Nat. Protoc. 4, 256-269 (2009).
36. Barnabas, R.V. & Celum, C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr. HIV Res. 10, 228-237 (2012).
37. Palù, G., Benetti, L. & Calistri, A. Molecular basis of the interactions between herpes simplex viruses and HIV-1. Herpes 8, 50-55 (2001).
38. Cunningham, A.L. et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194 (Suppl 1), S11-S18 (2006).
39. Huang, W. et al. Herpes simplex virus type 2 infection of human epithelial cells induces CXCL9 expression and CD4+ Tcell migration via activation of p38-CCAAT/enhancer-binding protein-β pathway. J. Immunol. 188, 6247-6257 (2012).
40. Pham, P.A. & Gallant, J.E. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin. Drug Metab. Toxicol. 2, 459-469 (2006).
41. Dobard, C. et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 86, 718-725 (2012).
42. Grobler, A. & Abdool Karim, S. Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. AIDS 26, 2261 (2012). author reply 2262-3.
43. Naranbhai, V. et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J. Infect. Dis. 206, 993-1001 (2012).
44. Robbins, B.L., Wilcox, C.K., Fridland, A. & Rodman, J.H. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23, 695-701 (2003).
45. Balzarini, J., Van Herrewege, Y. & Vanham, G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 16, 2159-2163 (2002).
46. Goicoechea, M. et al. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 24, 707-716 (2010).
47. Ballzarini, J. et al. A Multi-targeted drug candidate with dual anti-HIV and anti-HSV activity. PloS Pathog. 9, e1003456 (2013).
48. Johnson, T.J. et al. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob. Agents Chemother. 56, 6272-6283 (2012).
49. Smith, J.M. et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc. Natl. Acad. Sci. USA 110, 16145-16150 (2013).
50. Asin, S.N., Heimberg, A.M., Eszterhas, S.K., Rollenhagen, C. & Howell, A.L. Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res. Hum. Retroviruses 24, 701-716 (2008).